Home / Health / Corcept Drug Halves Ovarian Cancer Death Risk
Corcept Drug Halves Ovarian Cancer Death Risk
23 Jan
Summary
- Experimental drug reduced death risk by 35% in ovarian cancer patients.
- Combination therapy showed a 30% reduction in disease progression.
- FDA decision on the drug combination is expected by July 11.
Corcept Therapeutics has reported significant findings from a late-stage clinical trial involving its experimental drug, relacorilant, for ovarian cancer. When administered alongside chemotherapy, relacorilant demonstrated a notable 35% reduction in the risk of death among patients with a specific type of ovarian cancer.
This combination therapy also successfully delayed cancer progression, meeting a key study objective with a 30% decrease in the risk of worsening disease. The trial involved 381 women whose cancer had become resistant to standard platinum-based treatments.
Patients receiving the relacorilant and nab-paclitaxel combination lived an average of 16 months, compared to 11.9 months for those treated with chemotherapy alone. The drug, which blocks the hormone cortisol, was found to be well-tolerated, showing no increase in side effects compared to chemotherapy alone.
The U.S. Food and Drug Administration is scheduled to review the drug combination for platinum-resistant ovarian cancer, with a decision anticipated by July 11.
